Effect of exenatide on inflammatory and oxidative stress markers in patients with type 2 diabetes mellitus.
Abstract Aim: This study was designed to determine the effect of exenatide on inflammatory and oxidative stress markers in type 2 diabetes mellitus (T2DM) patients who were suboptimally controlled with metformin and/or sulfonylurea. Subjects and Methods: Twenty-three patients with T2DM with inadequa...
| Publicado en: | Diabetes Technology & Therapeutics Vol. 13; no. 2; pp. 143 - 149 |
|---|---|
| Autores principales: | , , , , , , , , , |
| Formato: | research randomized controlled trial Journal Article |
| Publicado: |
Mary Ann Liebert, Inc.
2011 Feb
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104810996&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 104810996 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 15209156 N3C jtl: Diabetes Technology & Therapeutics issn: 15209156 maglogo: N pubinfo: dt: 2011 Feb vid: 13 iid: 2 pid: 1365 pub: Mary Ann Liebert, Inc. place: New Rochelle, New York artinfo: ui: 104810996 104810996 2010934923 NLM21284481 104810996 ppf: 143 ppct: 6 formats: tig: atl: Effect of exenatide on inflammatory and oxidative stress markers in patients with type 2 diabetes mellitus. aug: au: Wu JD Xu XH Zhu J Ding B Du TX Gao G Mao XM Ye L Lee KO Ma JH affil: 1 Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University , Nanjing, China . sug: subj: Antiinflammatory Agents, Non-Steroidal Therapeutic Use Antioxidants Therapeutic Use Diabetes Mellitus, Type 2 Blood Diabetes Mellitus, Type 2 Drug Therapy Hypoglycemic Agents Therapeutic Use Oxidative Stress Drug Effects Peptides Therapeutic Use Venoms Therapeutic Use Aged Antiinflammatory Agents, Non-Steroidal Administration and Dosage Antioxidants Administration and Dosage Biological Markers Blood Blood Glucose Analysis Body Mass Index Body Weight C-Reactive Protein Analysis Double-Blind Studies Glycated Hemoglobin Analysis Human Hypoglycemic Agents Administration and Dosage Inflammation Mediators Blood Insulin Resistance Male Middle Age Peptides Administration and Dosage Pilot Studies Prostaglandins Analogs and Derivatives Prostaglandins Blood Randomized Controlled Trials Venoms Administration and Dosage Aged: 65+ years Middle Aged: 45-64 years Male ab: Abstract Aim: This study was designed to determine the effect of exenatide on inflammatory and oxidative stress markers in type 2 diabetes mellitus (T2DM) patients who were suboptimally controlled with metformin and/or sulfonylurea. Subjects and Methods: Twenty-three patients with T2DM with inadequate glucose control were randomly divided into two groups: exenatide group (E group) (12 patients, 5 [mu]g b.d. x 4 weeks followed by 10 [mu]g b.d. x 12 weeks) and placebo group (P group) (11 patients). Glycosylated hemoglobin (HbA1c), the seven-point glucose profile, daily mean glucose, and glycemic excursion were determined. The effects of exenatide on 8-iso-prostaglandin F2[alpha] (PGF2[alpha]), monocyte chemoattractant protein-1 (MCP-1), and high-sensitivity C-reactive protein (hs-CRP) were investigated. Results: Exenatide treatment reduced body weight and body mass index (BMI) and improved HbA1c, the seven-point glucose profile, and daily mean glucose compared with placebo (P < 0.05). Limited glycemic excursion was found in the E group compared with the P group (P < 0.05), including a smaller SD and postprandial glucose excursion. In addition, the oxidative stress maker PGF2[alpha] was significantly reduced by exenatide treatment (P < 0.05). The inflammatory markers hs-CRP and MCP-1 were also significantly reduced in the E group compared with the P group (P < 0.05). PGF2[alpha] was significantly correlated with glycemic excursion (P < 0.05), whereas MCP-1 was significantly correlated with body weight, BMI, glycemic excursion, and HbA1c (P < 0.05 for all). Conclusions: Exenatide treatment reduced patient body weight and BMI, improved HbA1c and the seven-point glucose profile, reduced daily mean glucose, limited glycemic excursion, and reduced oxidative stress and inflammatory markers in patients of T2DM having inadequate glucose control. pubtype: Academic Journal doctype: research randomized controlled trial Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|